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Background: MicroRNAs (miRNAs) are a large group of negative gene regulators that potentially play a critical role
in tumorigenesis. Increasing evidences indicate that miR-145 acts a tumor suppressor in numerous human cancers.
However, its role in oral carcinogenesis remains poorly defined. The aim of this study is to determine expression
levels of miR-145 in oral squamous cell carcinomas (OSCCs) and normal mucosa tissues, and explore its biological
functions in OSCCs.
Methods: Reverse transcription quantitative real-time PCR (RT-qPCR) assay was used to evaluate expression levels of
miR-145. The biological functions of miR-145 were determined by cell proliferation and colony formation, cell cycle
and apoptosis, as well as cell invasion assay.
Results: MiR-145 was frequently down-regulated in OSCCs compared with normal mucosa tissues. Restoring miR-
145 expression in OSCC cells dramatically suppressed cell proliferation and colony formation, and induced G1 phase
arrest and cell apoptosis. Importantly, our data showed that miR-145 downregulated the expression of c-Myc and
Cdk6, which have previously been identified as two direct targets of miR-145.
Conclusions: Our data suggest that miR-145 exerts its tumor suppressor function by targeting c-Myc and Cdk6,
leading to the inhibition of OSCC cell growth. MiR-145 rescue may thus be a rational for diagnostic and therapeutic
applications in OSCC.
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Oral squamous cell carcinoma (OSCC) is the most com-
mon head and neck neoplasm, and the incidence of new
cases indicates a continuing rise in developing countries
[1]. Although the clinical outcome of OSCC has gra-
dually improved, the overall 5-year survival rate of
patients is still disappointing [2,3], reflecting limited ad-
vances in our understanding of the pathogenesis of this
disease and the molecular events that contributed to its
development. Thus, a better understanding of the mo-
lecular mechanisms driving oral carcinogenesis may lead
to new diagnostic and therapeutic approaches to this
disease, and improve the prognosis of OSCC patients.
Like other cancers, oral carcinogenesis involves gradual
accumulation of multiple genetic and epigenetic altera-
tions, leading to gain-of-function in oncogenes and loss-* Correspondence: mjji0409@163.com
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reproduction in any medium, provided the orof-function in tumor suppressor genes [4,5]. MicroRNAs
(miRNAs) are a class of small non-coding RNAs, which
play an important role in regulating gene function through
targeting mRNAs for translational repression or degrad-
ation [6-8]. Abnormalities of miRNA have been implicated
in the pathogenesis of a variety of human diseases, notably
neoplasms [9-11]. Overexpression of oncogenic miRNAs
or underexpression of tumor suppressor miRNAs plays a
critical role in tumorigenesis. One major tumor suppres-
sor miRNA, miR-145, which plays a crucial role in regula-
ting smooth muscle cell differentiation [12] and inducing
apoptosis [13], is downregulated in many cancers, inclu-
ding prostate, bladder and colon cancer, as well as B-cell
malignancies [14-17]. To date, a cohort of genes related to
different cancer pathways have been identified and vali-
dated as targeted genes of miR-145, such as Pai-1, Fascin1,
Oct-4, Sox-2, Klf4, c-Myc, IRS1, Muc1, Yes, Stat1, and
p70S6K1 [18-25], suggesting that miR-145 is an oncosup-
pressor and plays an important role in the initiation andd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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dences that the ectopic expression of miR-145 in cancer
cells leads to a loss in cell viability and induces cell death
[13,19,26]. It has been well known that downregulation of
miR-145 is caused by promoter hypermethylation in se-
veral cancers [27,28]. Additionally, the tumor suppressor
gene p53, which is inactivate in approximately 50% of
human cancers, upregulates miR-145 expression, whereas
the Ras oncogene downregulates its expression [28,29].
Although downregulation of miR-145 is found in an ani-
mal OSCC model [30], its role in human oral carcinoge-
nesis remains largely unknown.
In the present study, we investigated expression levels
of miR-145 in primary OSCCs and adjacent normal oral
tissues using reverse transcription quantitative real-time
PCR (RT-qPCR). Our data showed that miR-145 was
significantly downregulated in OSCCs compared with
normal oral tissues. We also demonstrated the miR-145
suppressed OSCC cell growth by targeting c-Myc and
Cdk6.
Results
MiR-145 is downregulated in OSCCs
Prompted by numerous studies of miR-145 downre-
gulation in several human cancers [14-17], we sought to
identify the role of miR-145 in oral carcinogenesis. We
analyzed the expression levels of miR-145 in a cohort of
OSCCs, adjacent normal tissues and normal mucosa
tissues by RT-qPCR. As shown in Figure 1, miR-145 ex-
pression was significantly decreased in OSCCs compared
with adjacent normal tissues and normal mucosa tissues.
However, there was no significant difference between ad-
jacent normal tissues and normal mucosa tissues. TheseFigure 1 MiR-145 is downregulated in OSCCs. Expression level of miR-1
normal mucosa tissues was evaluated using RT-qPCR. Small nuclear RNA (s
mean ± SD (insert). Details are described in the Materials and Methods. T, O
**, P <0.01.observations suggest that miR-145 may be an oncosup-
pressor in this cancer.
MiR-145 inhibits OSCC cell growth
To test the effect of miR-145 on OSCC cell growth, we
used miR-145 mimics to transfect human OSCC cell
line Tca8113. Increased expression of MiR-145 upon
transfection was confirmed by RT-qPCR (Figure 2A). As
demonstrated by MTT assays, miR-145 restoration dra-
matically inhibited OSCC cell proliferation (Figure 2B).
The inhibitory effect on OSCC cell growth was further
confirmed by colony formation and anchorage indepen-
dent growth assays. Compared to cells transfected with
miRNA control, the number of colonies was significantly
decreased in cells transfected with miR-145 mimics
(Figure 2C and D). Taken together, miR-145 exhibits
the growth inhibitory ability in Tca8113 cells and acts
as a potential tumor suppressor.
MiR-145 induces OSCC cell cycle arrest and apoptosis
Inhibition of cell growth in cancer cells is usually asso-
ciated with concomitant cell cycle arrest and activation
of cell death pathways. We therefore examined the con-
tribution of cell cycle arrest and apoptosis to the ob-
served growth inhibition of miR-145-transfected cells.
As shown in Figure 3, compared with miRNA control,
cell cycle was arrested at the G1 phase when cells
were transfected with miR-145 mimics. The percen-
tage of G1 phase was increased from 62.8% to 74.3%.
In addition, the apoptotic cell number increased in miR-
145-transfected cells compared with miRNA control-
transfected cells, particularly late apoptosis (P <0.05)
(Figure 4).45 in each individual case of OSCCs, adjacent normal tissues and
nRNA) U6 was used as an internal control. Data are presented as
SCC tissues; AN, adjacent normal tissues; N, normal mucosa tissues;
Figure 2 MiR-145 inhibits OSCC cell growth. (A) Restoration of MiR-145 expression in Tca8113 cells was evidenced by RT-qPCR. SnRNA U6 was
used as a normalized control. ***, P <0.001. (B) MiR-145 significantly inhibited cell proliferation in Tca8113 cells. *, P <0.05; **, P <0.01. The effect
of miR-145 on cell growth was further confirmed by colony formation (C) and anchorage independent growth assays (D). Left panel showed the
representative image of colony formation in Tca8113 cells transfected with miR-145 mimics and miRNA control. Quantitative analysis of colony
numbers is shown in the right panel. Details are described in the Materials and Methods. Data are presented as mean ± SD of values from three
different assays. *, P <0.05; **, P <0.01.
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As OSCC is a type of highly malignant tumor with a po-
tent capacity to invade locally and distant metastasis, we
next attempted to explore the effect of miR-145 resto-
ration on OSCC cell invasion. As shown in Figure 5, the
Matrigel assays showed that the number of cells that
passed through Matrigel-coated membrane into the
lower chamber was significantly lower in the miR-145-
transfected cells than in the miRNA control-transfected
cells (P <0.001), suggesting that miR-145 inhibited the
invasive potential of Tca8113 cells.
MiR-145 inhibits OSCC cell growth by targeting c-Myc
and Cdk6
c-Myc has a pivotal function in growth control, differen-
tiation and apoptosis, and its abnormal expression is as-
sociated with many tumors. Thus, we attempt to explore
whether miR-145-mediated inhibition of cell growth isdue to through targeting c-Myc oncogene. As shown in
Figure 6, c-Myc expression was dramatically decreased
in miR-145-transfected cells compared with miRNA
control-transfected cells whatever the mRNA or protein
level. We further confirmed that miR-145 was able to
downregulate the target genes of c-Myc, cyclin D1,
which were involved in cell cycle regulation. Additionally,
miR-145 significantly decreased Cdk6, a major cyclin D-
dependent kinase, which was identified as another putative
target of miR-145 [31]. These findings suggested that miR-
145 suppressed OSCC cell growth, at least in part, by
targeting c-Myc and Cdk6.
Discussion
It has been well established that miRNAs play critical
roles in the regulation of cell proliferation, and that
miRNA dysregulation is causally involved in the initi-
ation and progression of cancer [9-11]. The interaction
Figure 3 MiR-145 induces OSCC cell cycle arrest. Tca8113 cells were transiently transfected with miR-145 mimics and miRNA control.
After 72 h post-transfection, DNA content was measured by flow cytometry to determine cell cycle fractions. Representative flow cytometric
histograms of cells transfected with miR-145 mimics and miRNA control from three independent experiments are shown in panel A. The fraction
of cells in each cell cycle phase is indicated in panel B. PI, propidium iodide; *, P <0.05.
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pathways have added a new layer of complexity to regu-
late cell growth. Recently, changes of miRNA profile in
cancer cells and their roles in tumorigenesis have been
increasingly appreciated [32,33]. MiR-145 has been re-
ported to be frequently downregulated in various kinds
of cancers [14-17]. However, there is presently not very
much known about miR-145 involvement in oral car-
cinogenesis. In the present study, we attempt to investi-
gate miR-145 expression in OSCCs and adjacent normal
tissues, and explore its biological function in oral car-
cinogenesis. Our data show that compared with adjacent
normal tissues, miR-145 expression in OSCCs is signifi-
cantly downregulated, suggesting that miR-145 is a can-
didate tumor suppressor in the pathogenesis of OSCC.
Down-regulation or silencing of miR-145 may abolish
tumor suppression so as to contribute to oral tumori-
genesis. We thus test the putative tumor suppressor
function of miR-145 in OSCC. MiR-145 restoration inTca8113 cells shows significant growth-suppressing effect
by inhibiting cell proliferation and colony formation in the
present study. Furthermore, miR-145 re-expression in-
duces cell cycle arrest and apoptosis, further suggesting its
tumor suppressor function. These data are supported by
the findings in the other cancers that the ectopic expres-
sion of miR-145 in cancer cells leads to inhibition of cell
proliferation and induces cell death [13,19,26]. Although
the evidences have highlighted the importance of miR-145
as an oncosuppressor in OSCCs, the precise molecular
mechanisms remain largely unclear. To better understand
the tumor suppressive effect of miR-145 in oral tumori-
genesis, particularly inhibition of cell growth, we investi-
gate the effect of miR-145 on c-Myc and Cdk6 in the
present study. c-Myc plays its central role in promotion of
cell replication by driving quiescent cells into the cell
cycle, which is overexpressed in many cancers [34]. This
function is originally thought to be elicited mainly via acti-
vation of transcription of those c-Myc target genes that
Figure 4 MiR-145 induces OSCC cell apoptosis. Cell apoptosis is measured by flow cytometry analysis of Annexin V-FITC double-labeled
Tca8113 cells transfected with miR-145 mimics and miRNA control. (A) Flow cytometry profile represents Annexin V-FITC staining in x axis and
propidium iodide (PI) in y axis. Dual staining of cells with Annexin V-FITC and PI enabled categorization of cells into four regions. Region Q1
shows the necrotic cells, Q2 shows the late apoptotic cells, Q3 shows the live cells, and Q4 shows the early apoptotic cells. (B) The experiment
was repeated three times and data represent the average of the early apoptotic and late apoptotic cells. *, P <0.05.
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D2, E and A, Cdk4, e2f1, e2f2, Cdc25A and B, etc. [34,35].
Cdk6, one of members of the CDK family, is known to
play important roles in the cell cycle though binding to
cyclin D promotes the phosphorylation of tumor suppres-
sor Rb. Following Rb phosphorylation, cyclin E activates
Cdk2 to effect further phosphorylation of Rb, thereby en-
abling the cells to cross the G1 restriction point [36]. In
the present study, our data show that miR-145 down-
regulates c-Myc and its target gene cyclin D1, as sup-
ported by the findings in other cancers that miR-145
represses the expression of c-Myc and its downstream tar-
gets in colon cancer and non-small cell lung cancer
(NSCLC) [21,37]. Meanwhile, we find that miR-145 dra-
matically inhibits Cdk6 expression in Tca8113 cells. In line
with this study, a previous study has shown that miR-145
inhibits Cdk6 expression by direct targeting its 3’-UTR incolon cancer cells [31]. Taken together, we propose that
miR-145 regulates OSCC cell growth, at least partially,
by targeting c-Myc and Cdk6, and that loss of miR-145
may provide a selective growth advantage during oral
carcinogenesis.
Notably, we find that miR-145 inhibits OSCC cell
invasion in the present study. To be consistent with
our findings, a previous study shows that miR-145 in-
hibits the migration of microvascular cells in response to
growth factor gradients by directly targeting a transcrip-
tion factor Fli-1 [38]. Moreover, miR-145-mediated sup-
pression of cell invasion and metastasis is in part caused
by directly targeting MUC1 [23]. A recent study also
shows that miR-145 affects cell migration of glioblas-
toma (GB) in vitro and in vivo by directly targeting
NEDD9, implicating an important role of miR-145 in
GB invasion [39]. Given the invasive ability is one of the
Figure 5 MiR-145 inhibits OSCC cell invasion. Cells transfected with miR-145 mimics and miRNA control were starved overnight and then
seeded in the Transwell chambers coated with Matrigel for invasion assay. Following a 24 h-culture, non-invading cells in the upper chamber
were removed and invading cells were stained and calculated in four microscopic fields per sample. Details are described in the Materials and
Methods. Shown are representative images of invading cells (A). The bar graphs (B), corresponding to upper panels, show means ± SD of the
numbers of invading cells from three independent experiments. **, P <0.01.
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causes of poor prognosis, thus, miR-145 appears to be a
key factor for tumor aggressiveness.
Conclusions
In summary, our data show that miR-145 is significantly
downregulated in OSCCs compared with adjacent nor-
mal tissues. To our knowledge, the present of study is
the first to demonstrate that miR-145 inhibits OSCC cell
growth by targeting c-Myc and Cdk6. As this unique
feature of miR-145-mediated gene silencing in human
cancers, including OSCC, miR-145 may thus prove to be
a potential biomarker for cancer diagnosis and serves as
a new target for cancer therapy.
Materials and methods
Cell culture and tissues samples
Human OSCC cell line Tca8113 was obtained from China
Center for Type Culture Collection (Wuhan, China) and
routinely cultured at 37°C in RPMI 1640 medium with
10% fetal bovine serum (FBS). This study was approved by
the Institutional Review Board and Human Ethics Com-
mittee of the First Affiliated Hospital of Xi’an JiaotongUniversity School of Medicine. A total of 31 paraffin-
embedded tissues, including 21 OSCC and 10 adjacent
normal tissues, and 6 normal mucosa tissues were ran-
domly obtained from the First Affiliated Hospital of Xi’an
Jiaotong University School of Medicine. None of these pa-
tients received chemotherapy and radiotherapy and in-
formed consent was obtained from each patient before the
surgery. The histologic diagnosis of tumors was made and
agreed upon by at least two senior pathologists at Depart-
ment of Pathology of the Hospital based on World Health
Organization (WHO) criteria.
Cell transfection
The following siRNA duplexes (GenePharma Inc.,
Shanghai, China) were used to restore miR-145 expres-
sion: MiR-145 mimics, 5’-GUC CAG UUU UCC CAG
GAA UCC CU-3’; MiRNA control, 5’-AGG UAG UGU
AAU CGC CUU GTT-3’. Transfection of cells was per-
formed using Oligofectamine (Invitrogen, Carlsbad, CA)
according to the manufacturer’s protocol. Briefly, cells
were seeded in 6-well plates at 30-40% confluence 24 h
prior to transfection. MiR-145 mimics and miRNA con-
trol (30 nM each) were used for each transfection.
Figure 6 MiR-145 inhibits the expression of c-Myc, Cyclin D1, and Cdk6 in Tca8113 cells. Cells transfected with miR-145 mimics and
miRNA control were starved overnight and harvested. (A) Total RNA was isolated and RT-qPCR was performed to evaluate the expression of
c-Myc, Cyclin D1, and Cdk6. Details are described in the Materials and Methods. **, P <0.01. (B) Cell lysates were collected and subjected to
Western blotting assays. The biological functions of miR-145 in Tca8113 cells were determined by blotting c-Myc and its downstream target,
cyclin D1, as well as Cdk6. β-actin was used for loading control of Western blotting. Shown in the right portion of the panel is a quantitative
illustration of expression of the indicated proteins using densitometry to measure the density of the corresponding bands on Western blot
shown in the left portion of the panel.
Table 1 RT-qPCR primers used in the present study
Gene Primer sequences (5’-3’)




U6 RT primer: CGCTTCACGAATTTGCGTGTCAT
Forward primer: GCTTCGGCAGCACATATACTAAAAT
Reverse primer: CGCTTCACGAATTTGCGTGTCAT
c-Myc Forward primer: GCTGCTTAGACGCTGGATTT
Reverse primer: CACCGAGTCGTAGTCGAGGT
Cyclin D1 Forward primer: AGACCTTCGTTGCCCTCTGT
Reverse primer: AGTTGTTGGGGCTCCTCAG
Cdk6 Forward primer: TGGAGACCTTCGAGCACC
Reverse primer: CACTCCAGGCTCTGGAACTT
β-actin Forward primer: GCACAGAGCCTCGCCTT
Reverse primer: GTTGTCGACGACGAGCG
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real-time PCR (RT-qPCR)
Total RNA was extracted from cultured cells using
TRIzol (Takara Inc., Dalian, P.R. China) according to
the protocols supplied by the manufacturers. For paraffin-
embedded tissues, total RNA was isolated using the
RecoverAll TM Total Nucleic Acid Isolation Kit (Ambion,
TX, USA) according to the instructions of manufacturer.
The concentration and purity of RNA were determined
spectrophotometrically using the NanoDrop ND-1000
(NanoDrop Technologies, DE). cDNA was generated
using the PrimeScript® RT reagent Kit (Takara Co., Ltd,
Dalian, China) in a 20 μL final reaction volume containing
500 ng of RNA, 0.5 μL PrimeScript® RT Enzyme Mix, and
4 μL 5 × PrimeScript® Buffer, and 1 μL RT primer. Real-
time quantitative PCR assay was performed to evaluate
miR-145 expression using the SYBR Premix Ex TaqTM II
(Takara Co., Ltd, Dalian, China) on an FTC-3000TM Sys-
tem (Funglyn Biotech Inc., Toronto, Canada) according to
the instructions of manufacturer. According to the2-ΔΔCt
method [40], MiR-145 expression was normalized to small
nuclear RNA (snRNA) U6 to calculate the relative amount
of RNA present in each sample. The expression values of
c-Myc, Cyclin D1 and Cdk6 were normalized to β-actin.
Each sample was run in triplicate. The primer sequences
were presented in Table 1.Western blot analysis
Cells were lysed in RIPA buffer. Cellular proteins were
collected and subjected to 10% SDS-PAGE, and trans-
ferred onto PVDF membranes (Amersham Pharmacia
Biotech, Piscataway, NJ). The membranes were then
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anti-cyclin D1 and anti-Cdk6 were purchased from
Santa Cruz Biotechnology, Inc. Anti-β-actin was pur-
chased from Epitomics, Inc. This was followed by incu-
bation with horseradish peroxidase-conjugated anti-rabbit
or anti-mouse IgG antibodies from Santa Cruz Biotech-
nology, Inc., and antigen-antibody complexes were visua-
lized using the Western Bright ECL detection system
(Advansta, CA).
Cell proliferation, colony formation and anchorage
independent growth assays
MTT assay was performed daily over a 3-d time course
to evaluate cell proliferation. Cell culture was added with
10 μL of 5 mg/mL MTT agent (Sigma, Saint Louis, MO)
and incubated for 4 h, followed by addition of 150 μL of
DMSO and further 15-min incubation. The plates were
then read on a microplate reader using a test wavelength
of 570 nm and a reference wavelength of 670 nm.
For colony formation assay, cells (5 × 105 cells per
well) were seeded in 6-well plates and transfected with
miR-145 mimics or miRNA control for 24 h. The me-
dium was refreshed every 3 days. Surviving colonies
(≥50 cells per colony) were fixed with methanol, stained
with 1.25% crystal violet and counted under a light micro-
scope. For anchorage independent growth assay, 1 × 105
cells with different transfections were cultured into 6-well
plates with a bottom layer of 0.6% agar and a top layer of
0.3% agar, respectively. Following the hardening of soft
agar, plates were incubated at 37°C with 5% CO2. After
2 weeks of culture, colonies were photographed and coun-
ted under a light microscope.
Cell cycle analysis
Seventy-two hours after transfection, cells were harvested,
washed twice in PBS, and fixed in 70% ethanol on ice for
at least 30 min. Cells were then stained with propidium
iodide solution (50 μg/mL propidium iodide, 50 μg/mL
RNase A, 0.1% Triton-X, 0.1 mM EDTA). Cell cycles were
analyzed based on DNA contents by FACS using a Flow
Cytometer (BD Biosciences, NJ).
Apoptosis assay
Cells were transfected with miR-145 mimics or control
for 24 h. Forty-eight hours after transfection, cells were
harvested and resuspended with 500 μL of binding buf-
fer. The cell suspension was incubated with 5 μL annexin-
V-FITC and propidium iodide at room temperature for
20 min. The stained cells were analyzed on a Flow
Cytometer (BD Biosciences, NJ).
Cell invasion assay
Cell invasion assays were performed using Transwell
chambers (8.0 μm pore size; Millipore, MA), which werecoated with Matrigel (4 × dilution; 60 μL/well; BD Bio-
science, NJ), in 24-well plates. Chambers were pre-
coated with rat tail tendon collagen type 1 (0.5 mg/mL)
on the lower surface. Transfected cells were starved
overnight and then seeded in the upper chamber at a
density of 2 × 105cells/mL in 400 μL of medium con-
taining 0.5% FBS. Medium with 10% FBS (600 μL) was
added to the lower chamber. Following a 24 h-incuba-
tion at 37°C with 5% CO2, non-invading cells in the
upper chamber were removed with a cotton swab, and
invading cells were fixed in 100% methanol and stained
with 0.5% crystal violet in 2% ethanol. Photographs were
taken randomly for at least four fields of each mem-
brane. The number of invading cells was expressed as
the average number of cells per microscopic field over
four fields.
Statistical analysis
All the experiments were similarly done at least three
times. Most of the measurements were performed in
triplicate and some in duplicates. All statistical analyses
were performed using the SPSS statistical package (11.5,
Chicago, IL, USA). P < 0.05 was considered to be statisti-
cally significant. Unless indicated, the results shown in
the figures are representatives.
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